Study Reveals Promising Data on Nilotinib as a Therapy for Diffuse Systemic Sclerosis

Author: Patircia Silva
Date Published: August-2015
Source: Scleroderma News

A new study recently published in the journal Arthritis Research & Therapy provides encouraging data on a pilot study evaluating nilotinib (Tasigna™) as a therapy for diffuse systemic sclerosis. The study is entitled “Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial” and was developed by researchers at the Hospital for Special Surgery, the Geisel School of Medicine at Dartmouth and Weill Cornell Medical Center.